Acronyms of Clinical Trial Names: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| (22 intermediate revisions by 4 users not shown) | |||
| Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
''For other acronyms involved in clinical trials, click [[Clinical trial acronyms|here]]'' | ''For other acronyms involved in clinical trials, click [[Clinical trial acronyms|here]]'' | ||
| Line 11: | Line 11: | ||
{| cellspacing="1" cellpadding="1" border="1" | {| id="acronyms" cellspacing="1" cellpadding="1" border="1" | ||
| '''''Acronym''''' | | '''''Acronym''''' | ||
| '''''Trial Name''''' | | '''''Trial Name''''' | ||
| Line 274: | Line 274: | ||
|- | |- | ||
| [[AGENT-2]] | | [[AGENT-2]] | ||
| [[Angiogenic Gene Therapy Trial]] | | [[Angiogenic Gene Therapy Trial 2]] | ||
|- | |- | ||
| [[AGENT-3]] | | [[AGENT-3]] | ||
| Line 331: | Line 331: | ||
|- | |- | ||
| [[ALLHAT]] | | [[ALLHAT]] | ||
| [[Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial]] | | [[Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial]] | ||
|- | |- | ||
| Line 374: | Line 371: | ||
| [[AMIOVIRT]] | | [[AMIOVIRT]] | ||
| [[Amiodarone Versus Implantable Defibrillator In Patients With Nonischemic Cardiomyopathy And Asymptomatic Nonsustained Ventricular Tachycardia Study]] | | [[Amiodarone Versus Implantable Defibrillator In Patients With Nonischemic Cardiomyopathy And Asymptomatic Nonsustained Ventricular Tachycardia Study]] | ||
|- | |- | ||
| [[AMISTAD I]] | | [[AMISTAD I]] | ||
| Line 472: | Line 466: | ||
|- | |- | ||
| [[ARMYDA-2]] | | [[ARMYDA-2]] | ||
| [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty | | [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty 2]] | ||
|- | |- | ||
| [[ARMYDA-3]] | | [[ARMYDA-3]] | ||
| [[ | | [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty 3]] | ||
|- | |- | ||
| [[ARMYDA-4]] | | [[ARMYDA-4]] | ||
| Line 487: | Line 481: | ||
|- | |- | ||
| [[ARMYDA-RECAPTURE]] | | [[ARMYDA-RECAPTURE]] | ||
| [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty]] | | [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty-Recapture]] | ||
|- | |- | ||
| [[ARMYDA-RELOAD]] | | [[ARMYDA-RELOAD]] | ||
| Line 548: | Line 542: | ||
| [[ASPECT]] | | [[ASPECT]] | ||
| [[Asian Paclitaxel-Eluting Stent Clinical Trial]] | | [[Asian Paclitaxel-Eluting Stent Clinical Trial]] | ||
|- | |- | ||
| [[ASPECT-2]] | | [[ASPECT-2]] | ||
| Line 560: | Line 551: | ||
| [[ASPIRE]] | | [[ASPIRE]] | ||
| [[Arixtra Study In Percutaneous Coronary Intervention: A Randomized Evaluation]] | | [[Arixtra Study In Percutaneous Coronary Intervention: A Randomized Evaluation]] | ||
|- | |- | ||
| [[ASSENT 3]] | | [[ASSENT 3]] | ||
| [[The Assessment Of The Safety And Efficacy Of A New Thrombolytic Regimen (Assent)-3 Investigators. Efficacy And Safety Of Tenecteplase In Combination With Enoxaparin, Abciximab, Or Unfractionated Heparin: The Assent-3 Randomized Trial In Acute Mi]] | | [[The Assessment Of The Safety And Efficacy Of A New Thrombolytic Regimen (Assent)-3 Investigators. Efficacy And Safety Of Tenecteplase In Combination With Enoxaparin, Abciximab, Or Unfractionated Heparin: The Assent-3 Randomized Trial In Acute Mi]] | ||
|- | |- | ||
| | | [[ASSENT 3 PLUS]] | ||
| [[Assessment Of The Safety And Efficacy Of A New Thrombolytic Regimen]] | | [[Assessment Of The Safety And Efficacy Of A New Thrombolytic Regimen-3]] | ||
|- | |- | ||
| [[ASSENT-1]] | | [[ASSENT-1]] | ||
| [[Assessment Of The Safety Of A New Thrombolytic: Tnk-Tpa]] | | [[Assessment Of The Safety and Efficacy Of A New Thrombolytic: Tnk-Tpa]] | ||
|- | |- | ||
| [[ASSENT-2]] | | [[ASSENT-2]] | ||
| [[Assessment Of The Safety And Efficacy Of A New Thrombolytic: Tnk-Tpa]] | | [[Assessment Of The Safety And Efficacy Of A New Thrombolytic: Tnk-Tpa-2]] | ||
|- | |- | ||
| [[ASSENT-4 PCI]] | | [[ASSENT-4 PCI]] | ||
| Line 776: | Line 764: | ||
| [[BELLES]] | | [[BELLES]] | ||
| [[Beyond Endorsed Lipid Lowering With Ebt Scanning]] | | [[Beyond Endorsed Lipid Lowering With Ebt Scanning]] | ||
|- | |- | ||
| [[BENEDICT]] | | [[BENEDICT]] | ||
| Line 788: | Line 773: | ||
| [[BENEFIT]] | | [[BENEFIT]] | ||
| [[Betaferon (Betaseron In U.S.) In Newly Emerging Ms For Initial Treatment Information]] | | [[Betaferon (Betaseron In U.S.) In Newly Emerging Ms For Initial Treatment Information]] | ||
|- | |- | ||
| [[BENESTENT I]] | | [[BENESTENT I]] | ||
| Line 800: | Line 782: | ||
| [[BERT]] | | [[BERT]] | ||
| [[Beta Energy Restenosis Trial - 1]] | | [[Beta Energy Restenosis Trial - 1]] | ||
|- | |- | ||
| [[BESMART]] | | [[BESMART]] | ||
| [[Bestent In Small Arteries Trial]] | | [[Bestent In Small Arteries Trial]] | ||
|- | |- | ||
| [[BESSAMI]] | | [[BESSAMI]] | ||
| Line 818: | Line 794: | ||
| [[BEST]] | | [[BEST]] | ||
| [[Balloon Equivalent To Stent Trial]] | | [[Balloon Equivalent To Stent Trial]] | ||
|- | |- | ||
| [[BEST-ICD]] | | [[BEST-ICD]] | ||
| Line 833: | Line 806: | ||
| [[BETTER]] | | [[BETTER]] | ||
| [[Beta Radiation Trial To Eliminate Restenosis]] | | [[Beta Radiation Trial To Eliminate Restenosis]] | ||
|- | |- | ||
| [[BHACAS]] | | [[BHACAS]] | ||
| [[Early And Midterm Outcome After Off-Pump And On-Pump Surgery In Beating Heart Against Cardioplegic Arrest Studies (Bhacas 1 And 2): A Pooled Analysis Of Two Randomised Controlled Trials.]] | | [[Early And Midterm Outcome After Off-Pump And On-Pump Surgery In Beating Heart Against Cardioplegic Arrest Studies (Bhacas 1 And 2): A Pooled Analysis Of Two Randomised Controlled Trials.]] | ||
|- | |- | ||
| [[BHAT]] | | [[BHAT]] | ||
| Line 854: | Line 821: | ||
| [[BIP]] | | [[BIP]] | ||
| [[Bezafibrate Infarction Prevention Study]] | | [[Bezafibrate Infarction Prevention Study]] | ||
|- | |- | ||
| [[BIRD]] | | [[BIRD]] | ||
| Line 879: | Line 843: | ||
| [[Bone Marrow Transfer To Enhance St-Elevation Infarct Regeneration]] | | [[Bone Marrow Transfer To Enhance St-Elevation Infarct Regeneration]] | ||
|- | |- | ||
| | | [[BPAV]] | ||
| [[Balloon Prophylaxis Of Aneurysmal Vasospasm]] | | [[Balloon Prophylaxis Of Aneurysmal Vasospasm]] | ||
|- | |- | ||
| Line 914: | Line 878: | ||
| [[BRILLIANT]] | | [[BRILLIANT]] | ||
| [[Batimastat (Bb-94) Antirestenosis Trial Utilizing The Biodivysio Local Drug Delivery Pc Stent ]] | | [[Batimastat (Bb-94) Antirestenosis Trial Utilizing The Biodivysio Local Drug Delivery Pc Stent ]] | ||
|- | |- | ||
| [[BRITE]] | | [[BRITE]] | ||
| Line 926: | Line 887: | ||
| [[BRITE-SVG]] | | [[BRITE-SVG]] | ||
| [[Beta Radiation To Reduce In-Stent Restenosis In Saphenous Vein Grafts]] | | [[Beta Radiation To Reduce In-Stent Restenosis In Saphenous Vein Grafts]] | ||
|- | |- | ||
| [[CABERNET]] | | [[CABERNET]] | ||
| Line 953: | Line 911: | ||
| [[CACTUS]] | | [[CACTUS]] | ||
| [[Coronary Bifurcations: Application Of The Crushing Technique Using Sirolimus-Eluting Stents]] | | [[Coronary Bifurcations: Application Of The Crushing Technique Using Sirolimus-Eluting Stents]] | ||
|- | |- | ||
| [[CADILLAC]] | | [[CADILLAC]] | ||
| Line 968: | Line 923: | ||
| [[CAFE]] | | [[CAFE]] | ||
| [[Conduit Artery Function Evaluation]] | | [[Conduit Artery Function Evaluation]] | ||
|- | |- | ||
| [[CALM]] | | [[CALM]] | ||
| Line 980: | Line 932: | ||
| [[CALYPSO]] | | [[CALYPSO]] | ||
| [[Cylexin As An Adjunct To Lytic Therapy To Prevent Superoxide Reflow Injury]] | | [[Cylexin As An Adjunct To Lytic Therapy To Prevent Superoxide Reflow Injury]] | ||
|- | |- | ||
| [[CAMELOT]] | | [[CAMELOT]] | ||
| Line 992: | Line 941: | ||
| [[CAMIAT]] | | [[CAMIAT]] | ||
| [[Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (Pilot)]] | | [[Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (Pilot)]] | ||
|- | |- | ||
| [[CANDLE]] | | [[CANDLE]] | ||
| Line 1,004: | Line 950: | ||
| [[CANPAP]] | | [[CANPAP]] | ||
| [[Continuous Positive Airway Pressure For Heart Failure Patients With Central Sleep Apnea]] | | [[Continuous Positive Airway Pressure For Heart Failure Patients With Central Sleep Apnea]] | ||
|- | |- | ||
| [[CAPARES]] | | [[CAPARES]] | ||
| Line 1,021: | Line 964: | ||
|- | |- | ||
| [[CAPRICORN]] | | [[CAPRICORN]] | ||
| [[Carvedilol Post | | [[Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study]] | ||
|- | |- | ||
| [[CAPRIE]] | | [[CAPRIE]] | ||
| Line 1,055: | Line 992: | ||
| [[CAPTURE]] | | [[CAPTURE]] | ||
| [[Chimeric 7E3 Antiplatelet Therapy In Unstable Angina Refractory To Standard Treatment]] | | [[Chimeric 7E3 Antiplatelet Therapy In Unstable Angina Refractory To Standard Treatment]] | ||
|- | |- | ||
| [[CAPTURE Registry]] | | [[CAPTURE Registry]] | ||
| Line 1,088: | Line 1,022: | ||
| [[CARE-HD]] | | [[CARE-HD]] | ||
| [[Coenzyme Q10 And Remacemide: Evaluation In Huntington Disease]] | | [[Coenzyme Q10 And Remacemide: Evaluation In Huntington Disease]] | ||
|- | |- | ||
| [[CARE-HF]] | | [[CARE-HF]] | ||
| Line 1,099: | Line 1,030: | ||
|- | |- | ||
| [[CARESS-in-AMI: 30-Day and 1-Year Results]] | | [[CARESS-in-AMI: 30-Day and 1-Year Results]] | ||
| [[Combined Abciximab Reteplase Stent Study In Acute Myocardial Infarction]] | | [[Combined Abciximab Reteplase Stent Study In Acute Myocardial Infarction: 30-Day and 1-Year Results]] | ||
|- | |- | ||
| [[CARET]] | | [[CARET]] | ||
| Line 1,144: | Line 1,075: | ||
|- | |- | ||
| [[CAST]] | | [[CAST]] | ||
| [[Cardiac Arrhythmia Suppression Trial]] | |||
| [[Cardiac Arrhythmia Suppression Trial ]] | |||
|- | |- | ||
| [[CASTEMI]] | | [[CASTEMI]] | ||
| Line 1,155: | Line 1,083: | ||
| [[The Cardiac Arrhythmia Suppression Trial II]] | | [[The Cardiac Arrhythmia Suppression Trial II]] | ||
|- | |- | ||
| | | [[CASTLE]] | ||
| [[Candesartan Amlodipine Study Of Tolerability And Efficacy]] | | [[Candesartan Amlodipine Study Of Tolerability And Efficacy]] | ||
|- | |- | ||
| Line 1,181: | Line 1,109: | ||
| [[CAVATAS]] | | [[CAVATAS]] | ||
| [[Endovascular Versus Surgical Treatment In Patients With Carotid Stenosis In The Carotid And Vertebral Artery Transluminal Angioplasty Study (Cavatas)]] | | [[Endovascular Versus Surgical Treatment In Patients With Carotid Stenosis In The Carotid And Vertebral Artery Transluminal Angioplasty Study (Cavatas)]] | ||
|- | |- | ||
| [[CAVEAT I]] | | [[CAVEAT I]] | ||
| Line 1,191: | Line 1,116: | ||
| [[Coronary Angioplasty Versus Excisional Atherectomy Trial II]] | | [[Coronary Angioplasty Versus Excisional Atherectomy Trial II]] | ||
|- | |- | ||
| [CBT-CD]] | | [[CBT-CD]] | ||
| [[Cognitive Behavior Therapy For The Chronic Depressions]] | | [[Cognitive Behavior Therapy For The Chronic Depressions]] | ||
|- | |- | ||
| Line 1,250: | Line 1,175: | ||
| [[CHEESE]] | | [[CHEESE]] | ||
| [[Comparative Trial Of Hiv-Infected Patients Evaluating Efficacy And Safety Of Saquinavir-Enhanced Oral Formulation And Indinavir Given As Part Of A Triple Drug Therapy ]] | | [[Comparative Trial Of Hiv-Infected Patients Evaluating Efficacy And Safety Of Saquinavir-Enhanced Oral Formulation And Indinavir Given As Part Of A Triple Drug Therapy ]] | ||
|- | |- | ||
| [[CHF-STAT]] | | [[CHF-STAT]] | ||
| Line 1,262: | Line 1,184: | ||
| [[CHRISTMAS]] | | [[CHRISTMAS]] | ||
| [[Carvedilol Hibernating Reversible Ischaemia Trial]] | | [[Carvedilol Hibernating Reversible Ischaemia Trial]] | ||
|- | |- | ||
| [[CHS]] | | [[CHS]] | ||
| [[Cardiovascular Health Study]] | | [[Cardiovascular Health Study]] | ||
----- | |||
---- [[CHS]] | |||
---- [[Charleston Heart Study]] | |||
----- | |||
---- [[CHS]] | |||
---- [[Community Health Study]] | |||
----- | |||
---- [[CHS]] | |||
---- [[Congenital Heart Surgeons Society Study]] | |||
----- | |||
---- [[CHS]] | |||
---- [[Coronary Heart Study]] | |||
|- | |- | ||
| [[CIAO]] | | [[CIAO]] | ||
| Line 1,282: | Line 1,210: | ||
|- | |- | ||
| [[CIBIS III]] | | [[CIBIS III]] | ||
| [[ | | [[The Cardiac Insufficiency Bisoprolol Study III]] | ||
|- | |- | ||
| [[CIDS]] | | [[CIDS]] | ||
| Line 1,301: | Line 1,229: | ||
| [[CLASS]] | | [[CLASS]] | ||
| [[Celecoxib (Celebrex) Long-Term Arthritis Safety Study]] | | [[Celecoxib (Celebrex) Long-Term Arthritis Safety Study]] | ||
|- | |- | ||
| [[CLASSICS]] | | [[CLASSICS]] | ||
| Line 1,315: | Line 1,240: | ||
|- | |- | ||
| [[CLEAR PLATELETS-2]] | | [[CLEAR PLATELETS-2]] | ||
| [[Clopidogrel With Eptifibatide To Arrest The Reactivity Of Platelets]] | | [[Clopidogrel With Eptifibatide To Arrest The Reactivity Of Platelets-2]] | ||
|- | |- | ||
| [[CLEERE]] | | [[CLEERE]] | ||
| Line 1,322: | Line 1,247: | ||
| [[COACH]] | | [[COACH]] | ||
| [[Coordinating Study Evaluating Outcomes Of Advising And Counseling In Heart Failure]] | | [[Coordinating Study Evaluating Outcomes Of Advising And Counseling In Heart Failure]] | ||
|- | |- | ||
| [[COAST]] | | [[COAST]] | ||
| Line 1,343: | Line 1,265: | ||
| [[COMBINE]] | | [[COMBINE]] | ||
| [[Combining Medications And Behavorial Interventions ]] | | [[Combining Medications And Behavorial Interventions ]] | ||
|- | |- | ||
| [[COMET]] | | [[COMET]] | ||
| Line 1,358: | Line 1,277: | ||
| [[COMMIT/CCS-2 – Metoprolol]] | | [[COMMIT/CCS-2 – Metoprolol]] | ||
| [[Randomized, Placebo-Controlled Trial Of Early Metoprolol In 46,000 Acute Myocardial Infarction Patients]] | | [[Randomized, Placebo-Controlled Trial Of Early Metoprolol In 46,000 Acute Myocardial Infarction Patients]] | ||
|- | |- | ||
| [[COMPANION]] | | [[COMPANION]] | ||
| Line 1,378: | Line 1,294: | ||
|- | |- | ||
| [[COMPLY]] | | [[COMPLY]] | ||
| [[Compliment Inhibition In Myocardial Infarction Treated With Thrombolytics | | [[Compliment Inhibition In Myocardial Infarction Treated With Thrombolytics (Evaluation Of Iv Dosing Regimens Of H5G1.1-Scfv) Sponsors]] | ||
|- | |- | ||
| [[COMS]] | | [[COMS]] | ||
| Line 1,387: | Line 1,303: | ||
|- | |- | ||
| [[CONSENSUS II]] | | [[CONSENSUS II]] | ||
| [[The Effects Of The Early Administration Of Enalapril On Mortality In Patients With Acute Myocardial Infarction: Results Of The Cooperative New Scandin]] | | [[The Effects Of The Early Administration Of Enalapril On Mortality In Patients With Acute Myocardial Infarction: Results Of The Cooperative New Scandin-2]] | ||
|- | |- | ||
| [[CONVERTIBLE]] | | [[CONVERTIBLE]] | ||
| Line 1,394: | Line 1,310: | ||
| [[CONVINCE]] | | [[CONVINCE]] | ||
| [[Controlled Onset Verapamil Investigation Of Cardiovascular Endpoints Trial]] | | [[Controlled Onset Verapamil Investigation Of Cardiovascular Endpoints Trial]] | ||
|- | |- | ||
| [[COOL]] | | [[COOL]] | ||
| Line 1,405: | Line 1,318: | ||
|- | |- | ||
| [[COOL MI]] | | [[COOL MI]] | ||
| [[Cooling As An Adjunctive Therapy To Percutaneous Intervention In Patients With Acute Myocardial Infarction]] | | [[Cooling As An Adjunctive Therapy To Percutaneous Intervention In Patients With Acute Myocardial Infarction]] | ||
|- | |- | ||
| Line 1,415: | Line 1,325: | ||
| [[COPERNICUS]] | | [[COPERNICUS]] | ||
| [[Effect Of Carvedilol On Survival In Severe Chronic Heart Failure]] | | [[Effect Of Carvedilol On Survival In Severe Chronic Heart Failure]] | ||
|- | |- | ||
| [[COPPA]] | | [[COPPA]] | ||
| Line 1,439: | Line 1,346: | ||
| [[COURAGE]] | | [[COURAGE]] | ||
| [[Clinical Outcomes Utilizing Revascularization And Aggressive Drug Evaluation ]] | | [[Clinical Outcomes Utilizing Revascularization And Aggressive Drug Evaluation ]] | ||
|- | |- | ||
| [[COURT]] | | [[COURT]] | ||
| [[Contrast Utilization In High Risk Patients Undergoing Ptca]] | | [[Contrast Utilization In High Risk Patients Undergoing Ptca]] | ||
|- | |- | ||
| [[C-PORT]] | | [[C-PORT]] | ||
| Line 1,481: | Line 1,382: | ||
| [[CRIS]] | | [[CRIS]] | ||
| [[A Controlled Trial Of Verapamil In Patients After Acute Myocardial Infarction: Results Of The Calcium, Antagonist Reinfarction Italian Study]] | | [[A Controlled Trial Of Verapamil In Patients After Acute Myocardial Infarction: Results Of The Calcium, Antagonist Reinfarction Italian Study]] | ||
|- | |- | ||
| [[CRUISE]] | | [[CRUISE]] | ||
| Line 1,535: | Line 1,433: | ||
| [[DATATOP]] | | [[DATATOP]] | ||
| [[Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism]] | | [[Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism]] | ||
|- | |- | ||
| [[DAVID]] | | [[DAVID]] | ||
| Line 1,559: | Line 1,454: | ||
| [[DEBATE]] | | [[DEBATE]] | ||
| [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | | [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | ||
|- | |- | ||
| [[DEBATE II]] | | [[DEBATE II]] | ||
| [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | | [[Doppler Endpoints Balloon Angioplasty Trial Europe-2]] | ||
|- | |- | ||
| [[DEBUT]] | | [[DEBUT]] | ||
| Line 1,610: | Line 1,502: | ||
| [[DETAIL]] | | [[DETAIL]] | ||
| [[Diabetics Exposed To Telmisartan And Enalapril]] | | [[Diabetics Exposed To Telmisartan And Enalapril]] | ||
|- | |- | ||
| [[DIABETES]] | | [[DIABETES]] | ||
| Line 1,649: | Line 1,538: | ||
| [[DIG Enalapril]] | | [[DIG Enalapril]] | ||
| [[Enalapril Versus Digoxin In Patients With Congestive Heart Failure: A Multicenter Study (Canadian Enalapril Versus Digoxin Study Group)]] | | [[Enalapril Versus Digoxin In Patients With Congestive Heart Failure: A Multicenter Study (Canadian Enalapril Versus Digoxin Study Group)]] | ||
|- | |- | ||
| [[DIGAMI]] | | [[DIGAMI]] | ||
| Line 1,850: | Line 1,736: | ||
| [[ENABLE]] | | [[ENABLE]] | ||
| [[Effects Of The Endothelin Receptor Antagonist Bosentan On The Morbidity And Mortality In Patients With Chronic Heart Failure]] | | [[Effects Of The Endothelin Receptor Antagonist Bosentan On The Morbidity And Mortality In Patients With Chronic Heart Failure]] | ||
|- | |- | ||
| [[ENCOR]] | | [[ENCOR]] | ||
| [[Enrasentan Cooperative Randomized Evaluation]] | | [[Enrasentan Cooperative Randomized Evaluation]] | ||
|- | |- | ||
| [[ENCORE I]] | | [[ENCORE I]] | ||
| Line 1,870: | Line 1,750: | ||
|- | |- | ||
| [[ENDEAVOR III]] | | [[ENDEAVOR III]] | ||
| [[Randomized Comparison Of Zotarolimus-Eluting And Sirolimus-Eluting Stents In Patients With Coronary Artery Disease]] | | [[Randomized Comparison Of Zotarolimus-Eluting And Sirolimus-Eluting Stents In Patients With Coronary Artery Disease-3]] | ||
|- | |- | ||
| [[ENDEAVOR IV]] | | [[ENDEAVOR IV]] | ||
| [[Randomized Comparison Of Zotarolimus-Eluting And Paclitaxel-Eluting Stents In Patients With Coronary Artery Disease]] | | [[Randomized Comparison Of Zotarolimus-Eluting And Paclitaxel-Eluting Stents In Patients With Coronary Artery Disease-4]] | ||
|- | |- | ||
| [[ENDEAVOR-1]] | | [[ENDEAVOR-1]] | ||
| Line 1,883: | Line 1,763: | ||
| [[ENRICHD]] | | [[ENRICHD]] | ||
| [[Enhancing Recovery In Coronary Heart Disease]] | | [[Enhancing Recovery In Coronary Heart Disease]] | ||
|- | |- | ||
| [[ENTIRE]] | | [[ENTIRE]] | ||
| Line 1,898: | Line 1,775: | ||
| [[EPHESUS]] | | [[EPHESUS]] | ||
| [[Eplerenone Post-Ami Heart Failure Efficacy And Survival Study]] | | [[Eplerenone Post-Ami Heart Failure Efficacy And Survival Study]] | ||
|- | |- | ||
| [[EPIC]] | | [[EPIC]] | ||
| [[Evaluation Of C7E3 For The Prevention Of Ischemic Complications]] | | [[Evaluation Of C7E3 For The Prevention Of Ischemic Complications]] | ||
|- | |- | ||
| [[EPILOG]] | | [[EPILOG]] | ||
| [[Evaluation Of Ptca To Improve Long-Term Outcome By C7E3 Gp IIb/IIia Receptor (Abciximab) Blockade]] | | [[Evaluation Of Ptca To Improve Long-Term Outcome By C7E3 Gp IIb/IIia Receptor (Abciximab) Blockade]] | ||
|- | |- | ||
| [[EPISTENT]] | | [[EPISTENT]] | ||
| Line 2,010: | Line 1,878: | ||
| [[Exercise Training Intervention After Coronary Angioplasty: The Etica Trial]] | | [[Exercise Training Intervention After Coronary Angioplasty: The Etica Trial]] | ||
|- | |- | ||
| | | [[ETROP]] | ||
| [[Early Treatment Of Retinopathy Of Prematurity]] | | [[Early Treatment Of Retinopathy Of Prematurity]] | ||
|- | |- | ||
Latest revision as of 20:38, 8 August 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For other acronyms involved in clinical trials, click here
For detailed instructions on how to contribute to WikiDoc's Clinical Trials Wiki, click here